Title |
Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports
|
---|---|
Published in |
BMJ Open, September 2014
|
DOI | 10.1136/bmjopen-2014-005253 |
Pubmed ID | |
Authors |
Tom Jefferson, Mark A Jones, Peter Doshi, Chris B Del Mar, Rokuro Hama, Matthew J Thompson, Igho Onakpoya, Carl J Heneghan |
Abstract |
The Cochrane risk of bias tool is a prominent instrument used to evaluate potential biases in clinical trials. In three updates of our Cochrane review on neuraminidase inhibitors, we assessed risk of bias on the same trials using different levels of detail: the trials in journal publications, in core reports, and in full clinical study reports. Here we analyse whether progressively greater amounts of information and detail in full clinical study reports (including trial protocols, statistical analysis plans, certificates of analyses, individual participant data listings and randomisation lists) affected our risk of bias assessments. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 14 | 21% |
Spain | 6 | 9% |
United States | 5 | 7% |
Canada | 4 | 6% |
New Zealand | 2 | 3% |
Chile | 2 | 3% |
Nigeria | 1 | 1% |
Australia | 1 | 1% |
Ecuador | 1 | 1% |
Other | 4 | 6% |
Unknown | 28 | 41% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 43 | 63% |
Practitioners (doctors, other healthcare professionals) | 13 | 19% |
Scientists | 10 | 15% |
Science communicators (journalists, bloggers, editors) | 2 | 3% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 43 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 7 | 16% |
Researcher | 6 | 14% |
Professor > Associate Professor | 4 | 9% |
Student > Bachelor | 3 | 7% |
Other | 3 | 7% |
Other | 11 | 26% |
Unknown | 9 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 24 | 56% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
Neuroscience | 2 | 5% |
Agricultural and Biological Sciences | 2 | 5% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Other | 2 | 5% |
Unknown | 10 | 23% |